RoleofAcademicDrugDiscoveryintheQuestforNewCNSTherapeutics
- 文档达人
-
2 次阅读
-
0 次下载
-
2021-01-05 11:30:59
微信
赏
支付宝
文档简介：
RoleofAcademicDrugDiscoveryintheQuestforNewCNSTherapeuticsBrianH.Yokley,†,∥MatthewHartman,‡,∥andBarbaraS.Slusher*,§†GEHealthcareLifeSciences,Marlborough,Massachusetts01752,UnitedStates‡AcademicDrugDiscoveryConsortium,Baltimore,Maryland21205,UnitedStates§JohnsHopkinsDrugDiscovery,DepartmentsofNeurology,Neuroscience,Psychiatry,Medicine,andOncology,JohnsHopkinsSchoolofMedicine,Baltimore,Maryland21205,UnitedStatesABSTRACT:Therewasagreaterthan50%declineincentralnervoussystem(CNS)drugdiscoveryanddevelopmentprogramsbymajorpharmaceuticalcompaniesfrom2009to2014.Thisdeclinewasparalleledbyariseinthenumberofuniversityleddrugdiscoverycenters,manyintheCNSarea,andagrowthinthenumberofpublic−privatedrugdiscoverypartnerships.Diverseoperatingmodelshaveemergedastheacademicdrugdiscoverycentersadapttothischangingecosystem.KEYWORDS:Academicdrugdiscovery,public-privatepartnershipsMajorpharmaceuticalcompanieshavedownsizedtheircentralnervoussystem(CNS)researchanddevelop-mentprograms.Inthe5-yearperiodbetween2009and2014,therewasa52%dropinthenumberoftotalCNSdrugdiscoveryanddevelopmentprogramspursuedbylargepharma,withalmostallcompaniesshowingadecline1(Figure1).Thisdecreasehasbeenattributedinparttochallengesintargetidentificationandvalidation,predictiveneurologicalanimalmodels,relevantbiomarkers,andheterogeneousclinicalsymptomswhichcontributetogreaterriskinCNStherapydevelopmentwhencomparedtothatofothertherapeuticindications.2ConcurrentwiththedecreaseinPharmaCNSR&D,therehasbeenanincreaseinthenumberofbot
扫描二维码
评论
发表评论